Studies on the Staphylococcal Protein A as a Pharmacological Treatment for Autoimmune Movement Disorders

Science Press Release Distribution Services

Studies on the Staphylococcal Protein A as a Pharmacological Treatment for Autoimmune Movement Disorders

August 12, 2020 Biotechnology and Microbiology 0

Staphylococcal protein A (SpA) is a key virulence factor that enables Staphylococcus aureus to evade
host innate and adaptive immune response. The immunomodulatory properties of SpA have led to a
hypothesis that it may have pharmacological applications as a treatment for autoimmune disease.
Clinical trials are underway to test whether ultrapure SpA can be used to treat immune
thrombocytopenia and rheumatoid arthritis. Here, we propose to investigate the potential of
staphylococcal protein A as an innovative drug to manage autoimmune movement disorders.

Author(s) Details

Gemma Eftimiadi,
GNOSIS, NPO, Gruppo di Studio dei Disturbi Motori e Comportamentali del Bambino, Cuneo, Italy.

Costantino Eftimiadi
GNOSIS, NPO, Gruppo di Studio dei Disturbi Motori e Comportamentali del Bambino, Cuneo, Italy and Medicina Generale Convenzionata ASL CN1, Cuneo, Italy.

Piergiuseppe Vinai,
GNOSIS, NPO, Gruppo di Studio dei Disturbi Motori e Comportamentali del Bambino, Cuneo, Italy.

View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/227

 

Leave a Reply

Your email address will not be published. Required fields are marked *